Genmab Reports Significant Survival and Response Benefits with Petosemtamab Combination in First-Line Head and Neck Cancer

Genmab Reports Positive Phase 3 LiGeR-HN1 Results for Petosemtamab Plus Pembrolizumab in Head and Neck Cancer Genmab A/S, a biotechnology company focused on developing innovative antibody-based medicines for serious diseases,…

Read MoreGenmab Reports Significant Survival and Response Benefits with Petosemtamab Combination in First-Line Head and Neck Cancer

Strand Therapeutics Doses First Patients in Clinical Trial of STX-003, a Tumor-Selective Programmable mRNA Therapy

Strand Therapeutics Doses First Patients in Phase 1 Trial of STX-003, a Programmable mRNA Therapy for Solid Tumors Strand Therapeutics, a clinical-stage biotechnology company developing programmable messenger RNA (mRNA) medicines,…

Read MoreStrand Therapeutics Doses First Patients in Clinical Trial of STX-003, a Tumor-Selective Programmable mRNA Therapy

REDEMPLO® (Plozasiran) Offers New Triglyceride-Lowering Treatment Option for Adults with FCS in England and Wales

Arrowhead Pharmaceuticals’ REDEMPLO Gains NICE Recommendation for NHS Treatment of Familial Chylomicronaemia Syndrome in England and Wales Arrowhead Pharmaceuticals’ REDEMPLO® (plozasiran) has received a positive funding recommendation from the National…

Read MoreREDEMPLO® (Plozasiran) Offers New Triglyceride-Lowering Treatment Option for Adults with FCS in England and Wales